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Abstract
Background:  Although both animal and human studies suggested the association between
placenta growth factor (PlGF) and chronic obstructive pulmonary disease (COPD), especially lung
emphysema, the role of PlGF in the pathogenesis of emphysema remains to be clarified. This study
hypothesizes that blocking PlGF prevents the development of emphysema.
Methods: Pulmonary emphysema was induced in PlGF knock-out (KO) and wild type (WT) mice
by intra-tracheal instillation of porcine pancreatic elastase (PPE). A group of KO mice was then
treated with exogenous PlGF and WT mice with neutralizing anti-VEGFR1 antibody. Tumor
necrosis factor alpha (TNF-α), matrix metalloproteinase-9 (MMP-9), and VEGF were quantified.
Apoptosis measurement and immuno-histochemical staining for VEGF R1 and R2 were performed
in emphysematous lung tissues.
Results: After 4 weeks of PPE instillation, lung airspaces enlarged more significantly in WT than in
KO mice. The levels of TNF-α and MMP-9, but not VEGF, increased in the lungs of WT compared
with those of KO mice. There was also increased in apoptosis of alveolar septal cells in WT mice.
Instillation of exogenous PlGF in KO mice restored the emphysematous changes. The expression
of both VEGF R1 and R2 decreased in the emphysematous lungs.
Conclusion: In this animal model, pulmonary emphysema is prevented by depleting PlGF. When
exogenous PlGF is administered to PlGF KO mice, emphysema re-develops, implying that PlGF
contributes to the pathogenesis of emphysema.
Background
Chronic obstructive pulmonary disease (COPD) affects
over 18 million Americans and is the 4th leading cause of
death in the US. The disease burden will continue to
increase globally as smoking rates climb in most develop-
ing countries [1]. Emphysema, a major component of
COPD, is characterized by variable inflammatory cell
infiltration, including neutrophils, alveolar macrophages,
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and CD4+ and CD8+ lymphocytes, as well as the presence
of proteinase-anti-proteinase imbalance within the alveo-
lar space, which leads to destruction and permanent
enlargement of peripheral lung airspaces [2-6]. Pulmo-
nary emphysema is defined as the abnormal enlargement
of respiratory spaces with destruction of the alveolar
walls. Experimental evidence supports the concept that
proteases from activated macrophages and neutrophils
degrade elastin and other structural proteins, thereby
damaging alveolar units [5,7].
The "vascular hypothesis" of COPD is corroborated by a
recent study showing that protein levels and messenger
ribonucleic acid (mRNA) expression of both VEGF and its
receptor are decreased in lung tissues of COPD patients
[8]. Moreover, cigarette smoke disrupts components of
the VEGF165-VEGFR2 and decreases the expression of
VEGF and its receptors in the lungs of rats and humans
[9]. Thus, VEGF signaling is considered mandatory for the
maintenance of alveolar structures.
Placenta growth factor (PlGF) is an angiogenic growth fac-
tor, which is a 50-kDa glycosylated dimeric protein shar-
ing 53% sequence homology at the amino acid level with
VEGF [10]. Like VEGF, it exhibits mitogenic activity in cul-
tured endothelial cells and induces angiogenesis in vivo
[11]. PlGF mRNA is abundant in the placenta, thyroid,
and lungs [12], but its biologic function in these tissues
remains largely unclear. A previous study involving PlGF-
transgenic mice demonstrates significantly enlarged air
spaces and enhanced pulmonary compliance, a situation
mimicking human pulmonary emphysema [13]. The
increased PlGF expression was also shown in COPD
patients [14].
Based on our previous results from transgenic mice and
human subjects, it is postulated that PlGF may be
involved in the inflammatory process related to emphy-
sema. This study aimed to test this hypothesis by deter-
mining whether emphysema could be prevented in mice
whose PlGF had been knocked out. It further aimed to
elucidate the role of PlGF in the pathogenesis of emphy-
sema.
Methods
Animals
The Animal Care and Use Committee of the National Tai-
wan University Hospital approved the following animal
protocol. Breeding couples of wild-type (PlGF +/+), heter-
ozygous type (PlGF +/-), and PlGF knock-out type (PlGF-/
-) mice in a 50% 129Sv × 50% Swiss background were per-
formed as described [15]. These mice were available from
the Dr. Peter Carmeliet's animal lab. In breeding rooms,
we maintained on a 12-hr light and dark cycle with con-
stant temperature and humidity.
Experimental animals and PPE-induced emphysema
The129/sw mice were anesthetized with intra-peritoneal
urethane (120 mg/100 g) and given porcine pancreatic
elastase (PPE) (Worthington; Biochem) at 4 mg/kg or
saline (0.9% NaCl) alone via intra-tracheal instillation
every week. These mice were then divided into 4 groups (n
= 5 each), including the wild type (PlGF +/+, WT with
PPE), heterozygous deficient (PlGF +/-, HE with PPE),
homozygous deficient (PlGF -/-, KO with PPE), and con-
trol (PlGF +/+, PlGF +/- and PlGF -/- with saline; C, C+/-
and C-/-, respectively). After 4 weeks of continuous treat-
ment, the mice were sacrificed for study. After being anes-
thetized and exsanguinated, their lungs were inflated until
visibly taut (maximum volume) with freshly prepared
paraformaldehyde through tracheal cannula. The maxi-
mum volume was maintained for at least 2 minutes
before the trachea was tied-off to maintain inflation. Two
transverse tissue slabs were cut from the lungs and one
from the right caudal lobe. The same locations were sam-
pled in all mice. These tissues were embedded in paraffin
and 4-μm serial sections were cut, individually handled
and numbered, and transferred on to the slides.
Second, the PlGF KO mice were evaluated if they could re-
develop emphysema. In these mice, PPE instillation fol-
lowed by exogenous PlGF at 1 mg/kg dose via intra-tra-
cheal route was done weekly. After 4 weeks, these KO mice
were studies for measurement of airspace enlargement.
Third, the PlGF WT mice were instilled with PPE followed
by VEGF R1 blocker agent (neutralizing antibody against
mouse VEGF-R1, AF471; R&D Systems) at a dose of 10 μg/
kg every week. After 4 weeks, these mice were sacrificed to
measure emphysema development.
Morphologic evaluation and quantification of emphysema
Quantitative histological measurements were made using
an image analysis system, consisting of an Olympus CCD
camera (Olympus, Tokyo, Japan). From each field, five
areas of interest, free of airway and muscular blood ves-
sels, were picked for measuring the number of intersec-
tions of virtual lines of known length with alveolar septa
[16]. An increase in the average distance between Mean
Linear Intercept (MLI) indicates enlarged airspaces. The
areas of interest were also analyzed for tissue area and
lung-air area. Volume density of the airspace (V v(air, lung)
%) was also measured [17].
Expression of inflammatory mediators and VEGF in 
bronchoalveolar lavage by ELISA
A 22-gauge cannula was inserted into the trachea, and
both lungs were lavaged five times with 0.8 ml of PBS. The
collected fluid was centrifuged at 400 × g for 10 minutes.
The supernatant (bronchoalveolar lavage fluid) were
divided into aliquots and stored at -80°C until analysis.Respiratory Research 2009, 10:115 http://respiratory-research.com/content/10/1/115
Page 3 of 10
(page number not for citation purposes)
The quantification for TNF-alpha, MMP-9 and VEGF were
assayed by standardized sandwich enzyme-linked immu-
nosorbent assay (ELISA) method (R&D Systems, Minne-
apolis, MN, USA) in duplicate according to the
manufacturer's protocol.
Western Blot analysis for TNF-alpha, MMP-9, VEGF, 
VEGFR1 and VEGFR2
Excised lungs were homogenized in a solution containing
1 mM EDTA, 0.5 mM aminoethylbenezenesulfonyl fluo-
ride (AEBSF), 1 μg/ml Leupeptin, 1 μg/ml Aprotinin, 10
μg/ml Trypsin-Chymotrypsin inhibitor, 1 μg/ml Pepstatin
A (all from Sigma). Proteins were resolved on 10% poly-
acrylamide gel and Western blots performed using stand-
ard techniques. Membranes were incubated overnight at
4°C with the following antibodies from Santa Cruz Bio-
chemicals (Santa Cruz, CA): anti-MMP-9 diluted 1:500;
anti-TNF-α diluted 1: 1000; anti-VEGF diluted 1: 1000;
anti-VEGFR1 diluted 1: 1000; and anti-VEGFR2 diluted 1:
1000, respectively as the primary antibody, and a 1:600
dilution of anti-goat IgG-horseradish peroxidase (Santa
Cruz, Cat # SC-2020) as the secondary antibody
Quantification of apoptotic cell assay in emphysematous 
lungs
In situ nick end-labeling (TUNEL) was performed using
the in situ cell death detection kit, Fluorescein (Roche,
Applied Science. Cat. No.11684795910), which was also
used for detecting and quantifying apoptosis (pro-
grammed cell death) at the single cell level, based on labe-
ling of DNA strand breaks (TUNEL technology). Analysis
was performed by fluorescence microscopy according to
the manufacturer's instructions and the number of fluo-
rescein-positive cells in the microscopic fields of each sec-
tion was determined by fluorescence microscope.
Immuno-histochemical staining for VEGF receptor
Paraffin-embedded tissue sections were treated with
xylene to remove the paraffin, and then dehydrated in eth-
anol, and re-hydrated in PBS. Endogenous peroxidase
activity was neutralized by incubating the sections for 20
min in 3% H2O2. After blocking the non-specific binding
sites with 3% BSA and 5% normal goat serum, the section
were incubated with primary antibodies for 1 h at room
temperature. The primary antibodies were mouse mono-
clonal antibodies against VEGF R1 and R2 (Chemicon
International, Inc. 1: 200 dilutions). Immuno-histochem-
ical staining of VEGF R1 (Flt-1) and R2 (KDR) was done
using standard techniques, with negative controls
obtained by omitting the primary antibody.
Statistical analysis
Statistical analysis was performed using the SPSS 9.0 for
Windows (Statistical Package for Social Sciences, Inc.,
Chicago, IL) and analyzed using the Mann-Whitney test
for non-parametric data. A p value < 0.05 was considered
statistically significant.
Results
Morphometric measurements of airspace size
The time course in developing emphysema after PPE
instillation was examined in these various genotypes of
mice. After 4 weeks of PPE treatment, there was marked
alveolar enlargement with breaks in the alveolar walls
compatible with destruction of the normal small airway
structure in WT mice (Fig. 1). However, this was not
present in PlGF KO mice (Fig. 2) and in saline control
groups (Fig. 3). The degree of airspace enlargement was
reduced in HE mice (Fig. 4).
Upon morphologic quantification of the severity of
emphysema by determining mean linear intercepts (MLI),
the values of which were significantly greater in WT mice
than in KO mice and controls (Fig. 5). Furthermore, the
volume density of airspaces (V, v(air, lung); %) was signifi-
cantly higher in WT mice (87.2 ± 0.6%) treated with PPE
for 4 weeks than the KO mice (71.8 ± 0.5%) (p < 0.01).
PlGF KO mice had less degree in the development of PPE-
induced emphysema. Besides, no significant MLI increase
was detected in heterozygous and homozygous deficiency
mice with saline treatment.
Photo-micrograph of lung parenchyma after PPE or normal  saline treatment - Wide type mice (PlGF +/+) treated with  PPE for 4 weeks show alveolar wall destruction Figure 1
Photo-micrograph of lung parenchyma after PPE or 
normal saline treatment - Wide type mice (PlGF +/+) 
treated with PPE for 4 weeks show alveolar wall 
destruction.
(original magnification X 40) Respiratory Research 2009, 10:115 http://respiratory-research.com/content/10/1/115
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Photo-micrograph of lung parenchyma after PPE or normal  saline treatment - displays marked enlargement of airspace as  compared to knock-out mice Figure 2
Photo-micrograph of lung parenchyma after PPE or 
normal saline treatment - displays marked enlarge-
ment of airspace as compared to knock-out mice.
(original magnification X 40) 
Photo-micrograph of lung parenchyma after PPE or normal  saline treatment - also displays marked enlargement of air- space as compared to the control group treated with normal  saline Figure 3
Photo-micrograph of lung parenchyma after PPE or 
normal saline treatment - also displays marked 
enlargement of airspace as compared to the control 
group treated with normal saline.
(original magnification X 40)
The severity of emphysema is considerably less in panel (PlGF  +/-, heterozygous type) (original magnification × 40; Bar =  100 μm) Figure 4
The severity of emphysema is considerably less in 
panel (PlGF +/-, heterozygous type) (original magnifi-
cation × 40; Bar = 100 μm). C: control.
(original magnification X 40) 
Emphysema in PPE-treated lung was assessed by mean linear  intercept (MLI) Figure 5
Emphysema in PPE-treated lung was assessed by 
mean linear intercept (MLI). MLIs are significantly 
greater in the wild type and heterogeneous mice, compared 
to the PlGF KO mice or control groups. (*p < 0.05, C: wide 
type mice with saline; C+/-: heterozygous mice with saline; 
C-/-: homozygous deficiency mice with saline). An decrease 
in MLIs and the degree of emphysematous change correlate 
with KO mice when compared with Fig. 1B.
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Decreased MMP-9 and TNF-alpha expression in lungs of 
PlGF KO mice
To assess if inflammatory mediators were affected in PlGF
KO mice, MMP-9 and TNF-alpha expression were ana-
lyzed after 4 weeks, as well as VEGF expression. The
expressions of both MMP-9 and TNF-alpha were lower in
the lungs of PlGF KO mice than in WT mice (Figs. 6 and
7). However, VEGF expression was higher in KO mice
than in the WT mice (Fig. 8), which revealed decreased
inflammatory reactions but increased vasculature in KO
mice after PPE instillation.
Decreased pulmonary septal cell death in lungs of PlGF KO 
mice
Assessment of apoptotic cells in the alveolar septa nor-
malized by fluorescence microscopy from serial sections
revealed an increase in TUNEL (+) cells in emphysema-
tous lungs when compared to those of PlGF KO mice
(Figs. 9 and 10). Quantification of the number of apop-
totic cells in the alveolar septa normalized by the amount
of nucleic acid extracted from serial sections revealed an
increase in TUNEL (+) cells in WT emphysematous lungs
when compared with the lungs of HE or KO mice (Fig.
11). There were significantly more TUNEL (+) cells in the
WT (emphysema, 11.8 ± 1.2%) than in KO mice (4.2 ±
1.3%) (p < 0.01).
Re-development emphysema after exogenous PlGF 
instillation in PPE-treated PlGF KO mice
PlGF KO mice were given weekly PPE instillation fol-
lowed by exogenous PlGF. Compared without exogenous
PlGF therapy (Fig 12), emphysematous changes were
detected within 2 weeks of concomitant therapy (Fig 13).
ELISA and Western blot analysis show higher expression of  MMP-9 in PlGF +/+ wild type mice, compared with PlGF -/-  KO mice Figure 6
ELISA and Western blot analysis show higher expres-
sion of MMP-9 in PlGF +/+ wild type mice, compared 
with PlGF -/- KO mice.
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ELISA and Western blot analysis show higher expression of  TNF-α in PlGF +/+ wild type mice, compared with PlGF -/-  KO mice Figure 7
ELISA and Western blot analysis show higher 
expression of TNF-α in PlGF +/+ wild type mice, 
compared with PlGF -/- KO mice.
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However, VEGF expression is higher in PlGF KO mice than  in wild type mice (*p < 0.05; **p < 0.01, C: wide type mice  with saline; C+/-: heterozygous mice with saline; C-/-:  homozygous deficiency mice with saline) Figure 8
However, VEGF expression is higher in PlGF KO 
mice than in wild type mice (*p < 0.05; **p < 0.01, C: 
wide type mice with saline; C+/-: heterozygous mice 
with saline; C-/-: homozygous deficiency mice with 
saline).
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Increased apoptotic cells in the alveolar septa of PlGF WT  mice Figure 9
Increased apoptotic cells in the alveolar septa of 
PlGF WT mice.
There is increased terminal deoxynucleotidyl (TdT)-mediated  dNTP nick end-labeling (TUNEL)-positive cells (fluorescent,  arrows) after a 4-week PPE treatment (original magnification  × 40, Bar = 100 μm) compared to KO mice Figure 10
There is increased terminal deoxynucleotidyl (TdT)-
mediated dNTP nick end-labeling (TUNEL)-positive 
cells (fluorescent, arrows) after a 4-week PPE treat-
ment (original magnification × 40, Bar = 100 μm) 
compared to KO mice.
TUNEL-positive cells are counted and represented in the  graph Figure 11
TUNEL-positive cells are counted and represented in 
the graph. There are significantly more TUNEL (+) cells in 
the emphysema lungs (PPE-treated WT mice) compared to 
the lungs of HE, KO, and control mice (p < 0.01, C: wide 
type mice with saline; C+/-: heterozygous mice with saline; 
C-/-: homozygous deficiency mice with saline). In PlGF KO 
mice, there is weekly PPE instillation followed by exogenous 
PlGF at a dose of 1 mg/kg via intra-tracheal route.
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KO mice treated with 4 weeks of PPE reveal no marked air- space enlargement Figure 12
KO mice treated with 4 weeks of PPE reveal no 
marked airspace enlargement.Respiratory Research 2009, 10:115 http://respiratory-research.com/content/10/1/115
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Airspace enlargement became more significant after 3-4
weeks. (Figs. 14, 15) Emphysema re-developed after exog-
enous PlGF instillation in PPE-treated PlGF KO mice,
which implied that PlGF contributed to the development
of emphysema.
PPE instillation followed by administration of neutraliz-
ing anti-VEGFR1 antibody AF471 decreased the develop-
ment of emphysema after 4 weeks. The MLIs values
decreased by 36% in the AF471 treatment group com-
pared to the controls (78 ± 17 vs. 60 ± 18, p = 0.06), which
did not reach statistical significance.
Decreased expression of immuno-histochemical staining 
for VEGF receptor
In the emphysematous tissues of WT mice treated with 4
week PPE, VEGF R1 (Flt-1) expression decreased as com-
pared to the WT control mice with saline that had no
emphysema (Figs. 16 and 17). Moreover, there was
Some emphysematous change is detected at 2 weeks of con- comitant therapy Figure 13
Some emphysematous change is detected at 2 weeks 
of concomitant therapy.
The airspaces are significantly enlarged after 3 weeks of  treatment Figure 14
The airspaces are significantly enlarged after 3 weeks 
of treatment.
The airspaces are markedly larger than before the 4-week  treatment, and emphysema re-develops (original magnifica- tion × 40, Bar = 100 μm) Figure 15
The airspaces are markedly larger than before the 4-
week treatment, and emphysema re-develops (origi-
nal magnification × 40, Bar = 100 μm).
Immuno-histochemical staining for VEGF R1 (Flt-1) and VEGF  R2 (KDR) Figure 16
Immuno-histochemical staining for VEGF R1 (Flt-1) 
and VEGF R2 (KDR). In Flt-1 expression, these are signifi-
cantly decreased in emphysematous lungs.Respiratory Research 2009, 10:115 http://respiratory-research.com/content/10/1/115
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reduced VEGF R2 (KDR) expression in lungs with emphy-
sematous changes (Figs. 18 and 19). Western blot analysis
also confirmed the reduced expression of these receptors
(Fig. 20).
Discussion
Pulmonary emphysema, defined as abnormal airspace
enlargement distal to the terminal bronchioles, is a major
component of COPD. Although COPD occurs predomi-
nantly in smokers, the fact that only 15-20% of smokers
develop pulmonary emphysema suggests an interaction
of genetic, environmental, and other factors in causing
emphysema [18-21]. The protease-anti-protease imbal-
ance and oxidative stress theories related to inflammation
are considered the key pathogenesis behind pulmonary
emphysema. However, inflammation may not be the sole
mechanism. Previously, studies reported the association
of VEGF with COPD [8,9]. In addition, Tsao et al. have
demonstrated that PlGF transgenic mice develop pathol-
ogy similar to human pulmonary emphysema, [13] while
humans with COPD show elevated PlGF levels in sera and
BAL fluids [14]. Taken together, angiogenic growth fac-
tors, such as PlGF, may contribute to the development of
emphysema.
The current study demonstrates that PlGF KO mice are
protected from developing elastase-induced emphysema.
It also shows lower apoptosis cell counts in PlGF KO mice
Immuno-histochemical staining for VEGF R1 (Flt-1) and VEGF  R2 (KDR) Displays Flt-1 expression comparison in controls  (arrows) Figure 17
Immuno-histochemical staining for VEGF R1 (Flt-1) 
and VEGF R2 (KDR) Displays Flt-1 expression com-
parison in controls (arrows).
In KDR expression, these are significantly decreased in  emphysematous lungs Figure 18
In KDR expression, these are significantly decreased 
in emphysematous lungs.
Displays KDR expression comparison in controls (arrows) Figure 19
Displays KDR expression comparison in controls 
(arrows). (original magnification × 200. Bar = 100 μm).
Western blot analysis shows lower VEGFR1 and VEGFR2  expression in emphysematous tissues compared to controls Figure 20
Western blot analysis shows lower VEGFR1 and 
VEGFR2 expression in emphysematous tissues com-
pared to controls.
Emphysema   Control
Flt-1 206kDa  
KDR 218kDa 
Actin     Respiratory Research 2009, 10:115 http://respiratory-research.com/content/10/1/115
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that did not develop emphysema, when compared to WT
mice that developed emphysema. Based on previous find-
ings [14], persistent PlGF treatment, combined with TNF-
α and IL-8, induces the down-regulation of VEGF in
human bronchial epithelial cells, most likely through
reduced number of viable cells and increased cell apopto-
sis. Tsao et al. have shown that PlGF inhibits the prolifer-
ation of MLE-15 cells (a mouse pulmonary type II
epithelial cell line) in a dose-dependent manner and sig-
nificantly promotes cell death [13]. Findings in cell cul-
ture studies are compatible with those from animals.
Moreover, intra-tracheal instillation of exogenous PlGF in
elastase-treated PlGF KO mice re-develops the emphyse-
matous pattern. We thought that PlGF is essential in the
pathogenesis of emphysema and is related to apoptosis.
Previously, it has been demonstrated that in vitro chronic
stimulation of epithelial cells with PlGF and other
cytokines induce cell death and apoptosis, which is simi-
lar to exposure to chronic irritants associated with in vivo
lung parenchymal damage [14]. A VEGFR inhibitor in a
concentration that mainly blocks VEGF R1 abolished this
phenomenon [14]. In this study, VEGF receptors, includ-
ing VEGF R1 and R2, have decreased expression in emphy-
sematous tissues. It is speculated that inflammatory
cytokines (i.e. TNF-α, IL-8) and PlGF-induced alveolar cell
apoptosis reduce the expression of VEGF and down-regu-
late VEGFR. These result in fewer endothelial cells and
thin, avascular alveolar septum that are compatible with
Liebow's opinion [22].
Recent studies pointed out that the failure to maintain
alveolar structure and lung apoptosis contributes to the
development of emphysema [23,24]. The defective home-
ostasis of one or more cell types elicit emphysematous
changes. For instance, when VEGF, which is abundant in
the lungs, is neutralized in animal models, the result is an
apoptosis-dependent enlargement of airspaces and struc-
tural changes similar to emphysema [25-27], not only by
induction of apoptosis of type II pneumocytes but also by
impaired production of surfactant [13,28]. An increasing
number of data, from animal models, studies on human
subjects, and cell culture experiments, supports an impor-
tant role for apoptosis in the pathogenesis of emphysema.
Thus, several disease mechanisms are involved in the
process, including inflammation, proteinase-anti-protein-
ase imbalance, and oxidative stress. Apoptosis interacts
with all of these pathways, adding to the complexity of the
disease.
PlGF expression increases significantly in early gestation,
peaks at around 26-30 weeks, and decreased as term
approaches [29]. However, the biological function of
PlGF after gestation and in adulthood remains unclear.
Although the synergism between VEGF and PlGF contrib-
utes to angiogenesis and plasma extravasation in patho-
logic conditions such as ischemia or inflammation [15], it
has been demonstrated that the bronchial epithelial cells
can express PlGF and elevated levels of PlGF have harmful
effects in COPD patients [14]. This animal study shows
that PlGF KO mice are protected against emphysema.
Since persistent and elevated PlGF levels may induce pul-
monary cell damage, inhibiting PlGF offers opportunities
for blocking the development of emphysema.
Several animal models of COPD development have been
previously studied. Compared to the chronic smoke expo-
sure model, the model of elastase-induced emphysema
develops more acutely, even though it may have more
limited clinical relevance, which included small airway
disease (bronchiolitis), airflow limitation, COPD exacer-
bation, systemic inflammation and extrapulmonary man-
ifestation. Some animal studies demonstrate that
inhibiting VEGFRs causes alveolar wall or endothelial cell
apoptosis, which is sufficient to cause emphysema. How-
ever, this does not lead to any accumulation of inflamma-
tory cells [26,30] or VEGF [31]. In the PPE-instillation
emphysema animal model, there is a substantial inflam-
matory response (MMP and TNF-α) accompanied by an
increase in cellular apoptosis and down-regulation of
VEGF levels, which are all relevant pathologic characteris-
tics of COPD.
Based on the previous in vitro study, the chronic activation
of epithelial cells with PlGF and other cytokines induces
cell death and apoptosis, which can be abolished by a
VEGF R1 inhibitor [14]. In this study, exogenous VEGF R1
blocker prevented emphysema in mice, with a trend of
decreased level of airspace enlargement. However, the
decrease expression of VEGF R1 and R2 in emphysema tis-
sues had not been expected. Aside from receptor blockers,
more studies should be performed to test whether apop-
tosis can be a therapeutic target to prevent emphysema.
In conclusion, this study demonstrates the hypothesis
that blocking PlGF can prevent the development of PPE-
induced emphysema in mice. The pathogenesis may be
related to the apoptosis. A VEGF R1 blocker partially
inhibited the action of exogenous PlGF and caused re-
development of emphysema. Identifying the cellular and
molecular mechanisms in the pathogenesis of emphy-
sema and apoptosis should have important implications
in developing new targets for therapeutic intervention of
COPD.
Competing interests
The authors declare that they have no competing interests.Respiratory Research 2009, 10:115 http://respiratory-research.com/content/10/1/115
Page 10 of 10
(page number not for citation purposes)
Authors' contributions
SLC carried out the animal studies, participating molecu-
lar biology experiments and drafted the manuscript. SJC
carried out the apoptosis with TUNEL stain. PC and PNT
participated in the source of the gene-deficient mice. SLC
and HCW participated in the design of the study and per-
formed the statistical analysis. CJY and PCY conceived of
the study, and participated in its design and coordination
and helped to draft the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
This study was supported by grants from the Far Eastern Memorial Hospital 
FEMH-95-C-005 (to S.L.C.), and NSC 94-2321-B-002-146- and NSC 95-
2314-B-002-044 (to. P.N.T.).
References
1. Peto R, Chen ZM, Boreham J: Tobacco: the growing epidemic.
Nat Med 1999, 5:15-17.
2. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC,
Rogers RM, Hayashi S, Hogg JC: Amplification of inflammation in
emphysema and its association with latent adenoviral infec-
tion.  Am J Respir Crit Care Med 2001, 164:469-493.
3. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cher-
niack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD: The
nature of small-airway obstruction in chronic obstructive
pulmonary disease.  N Engl J Med 2004, 350:2645-2653.
4. Ofulue AF, Ko M: Effects of depletion of neutrophils or macro-
phages on development of cigarette smoke-induced emphy-
sema.  Am J Physiol 1999, 21:L97-L105.
5. Dhami R, Gilks B, Xie C, Zay K, Wright JL, Churg A: Acute ciga-
rette smoke-induced connective tissue breakdown is medi-
ated by neutrophils and prevented by alpha1-antitrypsin.  Am
J Respir Cell Mol Biol 2000, 22:244-252.
6. Saetta M, DiStefano A, Turato G, Facchini FM, Corbino L, Mapp CE,
Maestrelli P, Ciaccia A, Fabbri LM: CD8+ T-lymphocytes in
peripheral airways of smokers with chronic obstructive pul-
monary disease.  Am J Respir Crit Care Med 1998, 157:822-826.
7. Churg A, Zay K, Shay S, Xie C, Shapiro SD, Hendricks R, Wright JL:
Acute cigarette smoke induced connective tissue break-
down requires both neutrophils and macrophage metalloe-
lastase in mice.  Am J Respir Cell Mol Biol 2002, 27:368-374.
8. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF:
Endothelial cell death and decreased expression of vascular
endothelial growth factor and vascular endothelial growth
factor receptor 2 in emphysema.  Am J Respir Crit Care Med 2001,
163:737-744.
9. Marwick JA, Stevenson CS, Giddings J, MacNee W, Butler K, Rahman
I, Kirkham PA: Cigarette smoke disrupts VEGF165-VEGFR-2
receptor signaling complex in rat lungs and patients with
COPD: morphological impact of VEGFR-2 inhibition.  Am J
Physiol Lung Cell Mol Physiol 2006, 290:L897-908.
10. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG: Iso-
lation of a human placenta cDNA coding for a protein
related to the vascular permeability factor.  Proc Natl Acad Sci
USA 1991, 88:9267-9271.
11. Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M, Pao-
letti I, Barra A, Tucci M, Parise G, Vincenti V, Granger HJ, Viglietto G,
Persico MG: Placenta growth factor-1 is chemotactic,
mitogenic, and angiogenic.  Lab Invest 1997, 76:517-531.
12. DiPalma T, Tucci M, Russo G, Maglione D, Lago CT, Romano A, Sac-
cone S, Della Valle G, DeGregorio L, Dragani TA, Viglietto G, Persico
MG: The placenta growth factor gene of the mouse.  Mamm
Genome 1996, 7:6-12.
13. Tsao PN, Su YN, Li H, Huang PH, Chien CT, Lai YL, Lee CN, Chen
CA, Cheng WF, Yu CJ, Hsieh FJ, Hsu SM: Overexpression of pla-
centa growth factor contributes to the pathogenesis of pul-
monary emphysema.  Am J Respir Crit Care Med 2004,
169:505-511.
14. Cheng SL, Wang HC, Yu CJ, Yang PC: Increased expression of
placenta growth factor in COPD.  Thorax 2008, 63:500-506.
15. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol
M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T,
Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriess-
che T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Char-
nock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG:
Synergism between vascular endothelial growth factor and
placental growth factor contributes to angiogenesis and
plasma extravasation in pathological conditions.  Nat Med
2001, 7(5):575-583.
16. Lucky EC, Keane J, Kuang PP, Snider GL, Goldstein RH: Severity of
elastase-induced emphysema is decreased in tumor necrosis
factor-alpha and interleukin-1 beta receptor-deficient mice.
Lab Invest 2002, 82:79-85.
17. Heemskerk-Gerritsen BA, Dijkman JH, Ten Have-Opbroek AA:
Stereological methods: a new approach in the assessment of
pulmonary emphysema.  Microsc Res Tech 1996, 34:556-562.
18. Shapiro DS: Vascular atrophy and VEGFR-2 signaling: old the-
ories of pulmonary emphysema meet new data.  J Clin Invest
2000, 106:1309-1310.
19. He JQ, Ruan J, Connett JE, Anthonisen NR, Pare PD, Sandford AJ:
Antioxidant gene polymorphisms and susceptibility to a
rapid decline in lung function in smokers.  Am J Respir Crit Care
Med 2002, 166:323-328.
20. Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T: Asso-
ciation of tumor necrosis factor alpha gene polymorphism
with the presence of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2001, 163:420-422.
21. Cheng SL, Yu CJ, Chen CJ, Yang PC: Genetic polymorphism of
epoxide hydrolase and glutathione S-transferase in COPD.
Eur Respir J 2004, 23:818-824.
22. Liebow AA: Pulmonary emphysema with special reference to
vascular change.  Am Rev Respir Dis 1959, 80:67-93.
23. Yoshida T, Tuder RM: Patho-biology of cigarette smoke-
induced chronic obstructive pulmonary disease.  Physiol Rev
2007, 87:1047-1082.
24. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG: Role of
apoptosis the pathogenesis of COPD and pulmonary emphy-
sema.  Respir Res 2006, 7:53.
25. Papaioannou AI, Kostikas K, Kollia P, Gourgoulianis KI: Clinical
implications for vascular endothelial growth factor in the
lung: friend or foe?  Respir Res 2006, 7:128.
26. Tang K, Rossiter HB, Wagner PD, Breen EC: Lung-targeted VEGF
in activation leads to an emphysema phenotype in mice.  J
Appl Physiol 2004, 97:1559-1566.
27. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman
S, Hirth PK, Waltenberger J, Voelkel NF: Inhibition of VEGF
receptors causes lung cell apoptosis and emphysema.  J Clin
Invest 2000, 106:1311-1319.
28. Lian X, Yan C, Yang L, Xu Y, Du H: Lysosomal acid lipase defi-
ciency causes respiratory inflammation and destruction in
the lung.  Am J Physiol Lung Cell Mol Physiol 2004, 286:L801-L807.
29. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ: Preeclampsia
is associated with reduced serum levels of placenta growth
factor.  Am J Obstet Gynecol 1998, 179:1539-1544.
30. Tuder RM, Zhen L, Cho CY, Taraseviviene-Stewart L, Kasahara Y,
Salvemini D, Voelkel NF, Flores SC: Oxidative stress and apopto-
sis interact and cause emphysema due to vascular endothe-
lial growth factor receptor blockade.  Am J Respir Cell Mol Biol
2003, 29:88-97.
31. Tang K, Rossiter HB, Wagner PD, Breen EC: Lung-targeted VEGF
inactivation leads to an emphysema phenotype in mice.  J
Appl Physiol 2004, 97:1559-1566.